Clusters of differentiation

Immutep Reports Positive Final Data from the INSIGHT-004 Phase I Study of LAG-3 Therapy, Efti, at ASCO 2021

Retrieved on: 
Friday, June 4, 2021
Health care, Clinical medicine, Medicine, Clusters of differentiation, Cancer immunotherapy, Orphan drugs, Immutep, Breakthrough therapy, Avelumab, PD-L1, Cancer research, LAG3

PD-L1 expression levels, MSI high or TMB)

Key Points: 
  • PD-L1 expression levels, MSI high or TMB)
    SYDNEY, AUSTRALIA, June 04, 2021 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep or the Company), a biotechnology company developing novel LAG-3 related immunotherapy treatments for cancer and autoimmune disease, announces encouraging final data from its Phase I INSIGHT-004 study.
  • It is being conducted under Immuteps collaboration with Merck KGaA, Darmstadt, Germany, and Pfizer Inc., which are co-developing and co-commercialising avelumab.
  • We are particularly encouraged to see the deep and durable responses in patients with solid tumors including PD-L1-negative cancers.
  • All responders (5/12) reported a partial response (PR) to the combination therapy according to RECIST 1.1

BeyondSpring Announces First Patient Dosed in a Triple Combination Study with Plinabulin, PD-1/PD-L1 Inhibitor and Radiotherapy for the Reversal of Resistance to PD-1/PD-L1 Inhibitors in Patients with Advanced Solid Tumors

Retrieved on: 
Friday, June 4, 2021
Cancer treatments, Clinical medicine, Medicine, Cancer immunotherapy, Clusters of differentiation, Breakthrough therapy, Orphan drugs, Antineoplastic drugs, Pembrolizumab, Programmed cell death protein 1, PD-L1, Plinabulin

The study is titled An Open-label, Single-center, Phase 1b/2 Study to Evaluate the Safety of Plinabulin in Combination with Radiation/Immunotherapy in Patients with Select Advanced Malignancies after progression on PD-1 or PD-L1 Targeted Antibodies.

Key Points: 
  • The study is titled An Open-label, Single-center, Phase 1b/2 Study to Evaluate the Safety of Plinabulin in Combination with Radiation/Immunotherapy in Patients with Select Advanced Malignancies after progression on PD-1 or PD-L1 Targeted Antibodies.
  • The first patient progressed on Keytruda and chemotherapy in first-line NSCLC, and has been dosed with RT, plinabulin (30 mg/m2) and Keytruda.
  • US FDA granted priority review for Plinabulin and G-CSF combination for CIN prevention with a PDUFA date of November 30, 2021.
  • Additionally, it is being broadly studied in combination with various immuno-oncology regimens that could boost the effects of PD-1/PD-L1 antibodies.

I-Mab to Hold Investor Call to Present In-Depth Phase 1 Clinical Data on Highly Differentiated CD73 Antibody Uliledlimab

Retrieved on: 
Wednesday, June 2, 2021
Clusters of differentiation, Branches of biology, Medical specialties, Clinical medicine, NT5E, Atezolizumab, Adenosine, Stromal cell

ET to provide an in-depth clinical data analysis of its U.S. phase 1 study of uliledlimab in combination with atezolizumab (TECENTRIQ) in patients with advanced cancers.

Key Points: 
  • ET to provide an in-depth clinical data analysis of its U.S. phase 1 study of uliledlimab in combination with atezolizumab (TECENTRIQ) in patients with advanced cancers.
  • ET via Zoom:
    Uliledlimab (TJD5) is a differentiated, humanized antibody against CD73, an ecto-enzyme expressed on stromal cells and tumors that converts extracellular adenosine monophosphate (AMP) to adenosine.
  • Uliledlimab is expected to offer clinical benefit by suppressing tumor growth in concert with checkpoint therapies such as PD-(L)1 antibodies.
  • Uliledlimab is effective in anti-tumor activities through a unique intra-dimer binding, leading to differentiated and favorable functional properties as evident in preclinical studies.

Immutep Enters Into A New Collaboration With Merck KGaA, Darmstadt, Germany For LAG-3 Therapy, Efti

Retrieved on: 
Tuesday, June 1, 2021
Clusters of differentiation, LAG3, Immutep, Eftilagimod alpha

Bintrafusp alfa aims to block two immunosuppressive pathways, TGF- and PD-L1, while efti activates antigen presenting cells, via the LAG-3 MHC II pathway.

Key Points: 
  • Bintrafusp alfa aims to block two immunosuppressive pathways, TGF- and PD-L1, while efti activates antigen presenting cells, via the LAG-3 MHC II pathway.
  • The new trial builds on our knowledge and the encouraging data from the INSIGHT trial of efti, also in solid tumours.
  • We are very pleased to be expanding our involvement with Immutep to explore efti in a new combination with bintrafusp alfa.
  • Immutep is financially supporting the trial to be run by IKF, and Merck, Darmstadt, Germany is financially contributing to the biomarker-related work.

TRACON Pharmaceuticals Announces Results of Independent Data Monitoring Committee Review of Safety Data from ENVASARC Pivotal Trial

Retrieved on: 
Tuesday, June 1, 2021
Clinical trials, Health sciences, Health, Medical research, Clusters of differentiation, Clinical endpoint, Clinical research, Pivotal trial, PD-L1, Breakthrough therapy

Based on the current accrual rate, we expect the Data Monitoring Committee to review additional safety data in the third quarter and to review interim efficacy data in the fourth quarter of this year.

Key Points: 
  • Based on the current accrual rate, we expect the Data Monitoring Committee to review additional safety data in the third quarter and to review interim efficacy data in the fourth quarter of this year.
  • Envafolimab (KN035), a novel, single-domain antibody against PD-L1, is the first subcutaneously injected PD-(L)1 inhibitor to be studied in pivotal trials.
  • The primary endpoint is ORR by blinded independent central review with duration of response a key secondary endpoint.
  • TRACON undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.

DGAP-News: VAXIMM to Attend International Scientific and Industry Events

Retrieved on: 
Thursday, May 27, 2021
Health care, Health sciences, Clinical medicine, Cancer immunotherapy, Clusters of differentiation, Avelumab, Breakthrough therapy, Merck Group, Immunotherapy, PD-L1, Pfizer, PD-1 and PD-L1 inhibitors

For updates, please see the Events section of the Company's website.

Key Points: 
  • For updates, please see the Events section of the Company's website.
  • VAXIMM is a privately held, Swiss/German biotech company that is developing oral T-cell immunotherapies for patients suffering from cancer.
  • As part of a scientific collaboration with Merck KGaA, Darmstadt, Germany, and Pfizer Inc., VAXIMM has an ongoing clinical trial evaluating VXM01 in combination with the human anti-PD-L1 antibody, avelumab.
  • Its wholly owned subsidiary, VAXIMM GmbH, located in Mannheim, Germany, is responsible for the Company's development activities.

VAXIMM to Attend International Scientific and Industry Events

Retrieved on: 
Thursday, May 27, 2021
Health care, Health sciences, Clinical medicine, Cancer immunotherapy, Breakthrough therapy, Orphan drugs, Clusters of differentiation, Avelumab, Merck Group, Immunotherapy, PD-L1, Pfizer

For updates, please see the Events section of the Companys website.

Key Points: 
  • For updates, please see the Events section of the Companys website.
  • VAXIMM is a privately held, Swiss/German biotech company that is developing oral T-cell immunotherapies for patients suffering from cancer.
  • As part of a scientific collaboration with Merck KGaA, Darmstadt, Germany, and Pfizer Inc., VAXIMM has an ongoing clinical trial evaluating VXM01 in combination with the human anti-PD-L1 antibody, avelumab.
  • Its wholly owned subsidiary, VAXIMM GmbH, located in Mannheim, Germany, is responsible for the Companys development activities.

BeyondSpring to Present at the Jefferies Virtual Healthcare Conference on June 3, 2021

Retrieved on: 
Wednesday, May 26, 2021
Clusters of differentiation, Life sciences, Immunology, Medical specialties, Immune system, PD-L1, Biotechnology, Cancer immunotherapy, Programmed cell death protein 1, Plinabulin, Biopharmaceutical, Molecular Partners

A video replay of the presentation will be available on the Events and Presentations investor section of the BeyondSpring website following the conference.

Key Points: 
  • A video replay of the presentation will be available on the Events and Presentations investor section of the BeyondSpring website following the conference.
  • Headquartered in New York City, BeyondSpring is a global biopharmaceutical company focused on developing innovative cancer therapies to improve clinical outcomes for patients who have high unmet medical needs.
  • BeyondSprings first-in-class lead asset plinabulin, is being developed as a pipeline in a drug.
  • Additionally, it is being broadly studied in combination with various immuno-oncology regimens that could boost the effects of PD-1 / PD-L1 antibodies.

GigaGen Publishes Research Describing Potential New Avenues to Overcome Resistance to anti-PD-L1 Therapies

Retrieved on: 
Tuesday, May 25, 2021
Clinical medicine, Medicine, Clusters of differentiation, Cancer immunotherapy, Health sciences, Immunotherapy, Virotherapy, PD-L1, Tumor microenvironment, Preclinical development, Tumor-associated macrophage

The preclinical data describes potential new avenues to overcome resistance to anti-PD-L1 therapies.

Key Points: 
  • The preclinical data describes potential new avenues to overcome resistance to anti-PD-L1 therapies.
  • Our preclinical data shed light on the molecular mechanisms of existingcancer immunotherapies, such as anti-PD-L1 and/or anti-TGF- therapy, and hints at potential new targets and novel therapeutic approaches for overcoming resistance to anti-PD-L1 oncology therapies.
  • GIGA-564 is designed to regulate immune response specifically in the tumor microenvironment, with potential to provide superior efficacy and reduced toxicity.
  • The analysis was complemented with in vivo testing to evaluate the potential anti-tumor activity of a newly discovered target, chemokine CCL5.

Protagonist Therapeutics Announces First Subject Dosed in Phase 1 Study of Oral IL-23 Receptor Antagonist PN-232

Retrieved on: 
Monday, May 24, 2021
Interleukins, Cytokines, Immune system, Branches of biology, Medical specialties, Clusters of differentiation

NEWARK, Calif., May 24, 2021 /PRNewswire/ --Protagonist Therapeutics, Inc.(Nasdaq:PTGX) today announced that the first human subject has been dosed in a Phase 1 study of PN-232,a novel oral interleukin-23 receptor (IL-23R) antagonist peptide.

Key Points: 
  • NEWARK, Calif., May 24, 2021 /PRNewswire/ --Protagonist Therapeutics, Inc.(Nasdaq:PTGX) today announced that the first human subject has been dosed in a Phase 1 study of PN-232,a novel oral interleukin-23 receptor (IL-23R) antagonist peptide.
  • "PN-232 is a second-generation, oral, IL-23 receptor antagonist candidate currently being developed in collaboration with Janssen Research & Development, LLC," said Dinesh V. Patel, Ph.D., President and Chief Executive Officer at Protagonist.
  • PTG-200 is an orally delivered, gut-restricted, interleukin-23 receptor specific antagonist peptide in a Phase 2 clinical trial for Crohn's disease.
  • PN-235 and PN-232, both second-generation oral interleukin-23 receptor antagonist candidates, are in Phase 1 studies.